Our research shows the transformative effect that alemtuzumab can have for people with MS.
Patients who continue to show disease activity while on their initial therapy are especially difficult to treat.
Now, we have shown that alemtuzumab works where first-line drugs have already failed.
It not only reduces the chances of disability associated with MS but may even result in long-term clinical improvements.
More top news
Entertainer made a blind woman feel "completely and utterly trapped" when he assaulted her in hospital bedroom, a court has been told.
A Border patrol on the frontier that separates Texas from Mexico hopes Donald Trump will keep his vow to tackle illegal immigration.
Donald Trump has urged the UK to "look at" ex-MI6 agent Christopher Steele to see if he was behind the controversial 35-page document.